DSIP
Delta sleep-inducing peptide — sleep architecture
5mg650.000 ₫
Delivery method:
Single vial
650.000 ₫
DSIP pen
845.000 ₫
DSIP (Delta Sleep-Inducing Peptide) is a nine-amino-acid neuropeptide first isolated from the cerebral venous blood of sleeping rabbits. It is the only peptide named for and characterised by a direct effect on slow-wave (delta) sleep architecture in published human work — no other peptide in the category has equivalent EEG-validated delta-wave evidence. Researched outcomes include increased slow-wave sleep, improved sleep continuity, normalised cortisol rhythm, and improved stress-resilience and recovery markers. Unlike sedative GABAergics it does not suppress REM or compress slow-wave sleep; it deepens what is already there. Most commonly dosed pre-bed in short cycles to avoid tolerance. A core component of the Sleep stack alongside Epithalon, which re-sets the pineal–melatonin clock that schedules the deeper sleep DSIP enables.
Dosage
Typical research dose: 100–300 mcg subcutaneously, 30–60 min before bed, in 5–10 day cycles.
Duration of effect
Short plasma half-life; sleep effects observed across the night
See full half-life table →Key Features
- Delta-wave sleep modulation
- Pre-bed cyclical dosing
- Stress & circadian support
- 5mg vial
Includes key details, half-life data, usage notes and research sources.
Usage Instructions
Subcutaneous injection as recommended. Consult a healthcare professional for protocols tailored to your goals.
Research Highlights
- Backed by scientific research
- Manufactured to pharmaceutical standards
- Used in clinical research settings
- Established safety profile
Safety Information
- •Consult your healthcare provider before use
- •Not intended for pregnant or nursing women
- •Store properly according to instructions
- •Report any adverse effects to your healthcare provider
Source: Kovalzon & Strekalova, PNAS (PMC, 1979)
Clinical Research
Delta sleep-inducing peptide produces a significant increase in slow-wave (delta) sleep and is associated with sleep-related growth hormone release — the foundational evidence that the peptide directly modulates deep-sleep architecture rather than acting as a generic sedative.
Read full studyAdditional Research
Source: Khudoerkov et al., Molecules (PMC, 2021)
DSIP demonstrates measurable neuroprotective and motor-recovery effects after focal cerebral ischaemia — supporting its broader role as a stress-buffering and CNS-recovery peptide beyond sleep architecture alone.
Read full studyHuman Clinical Trials
- DSIP in chronic insomniaNeuropsychobiology · 1981
Double-blind placebo-controlled crossover study in insomnia patients; clinical benefit was modest and inconsistent.
Small, old study with weak results.
Read the trial16participants